Market Analysis
BSX Shares Dip as Boston Scientific Unveils Biggest Deal in 20 Years
Boston Scientific stock slipped 3.6% in premarket trading after the company announced a $14.5 billion deal to buy Penumbra.
Total Stories
8
News
BSX
Section
BSX
Earnings
Earnings Recap: Boston Scientific, CME, and Johnson Controls Deliver Quarterly Beats
BSX, CME, and JCI have all reported strong earnings, surpassing expectations and demonstrating robust growth and resilience in their respective sectors.
Earnings
Boston Scientific Reports Strong Q3 2025 Results, Raises Full-Year Outlook
Boston Scientific reported Q3 2025 net sales of $5.07 billion and adjusted EPS of $0.75, topping expectations and supporting its upbeat full-year guidance.
Earnings
Boston Scientific (BSX) Beats Q2 Expectations with Strong Growth
Boston Scientific's Q2 2025 results exceeded expectations, with net sales of $5.061 billion and adjusted EPS of $0.75.
Uncategorized
Boston Scientific Corporation’s Q4 2024 Net Sales Surge by 22.4%, Exceeding Expectations
Boston Scientific Corporation reported robust financial results in Q4 2024, with net sales reaching $4.561 billion, a 22.4% increase from the previous year.
Earnings
BSX Reports $4.12 Billion in Q2 2024 Net Sales, Up 14.5% from Q2 2023
Boston Scientific Corporation (NYSE: BSX) has reported robust financial results for the second quarter of 2024.
Earnings
Boston Scientific (BSX) Beats Expectations with $3.8 Billion in Q1 Net Sales
Boston Scientific Corporation (NYSE: BSX) reported a significant growth in net sales for the first quarter of 2024, reaching $3.856 billion.
Earnings
Boston Scientific Corporation (BSX) Reports $0.50 Adjusted EPS, $3.73B Revenue for Q3
Boston Scientific reports Q3 results with a strong revenue of $3.73 billion and an adjusted EPS of $0.50.